512 related articles for article (PubMed ID: 31208095)
1. Phytochemicals as Modulators of Long Non-Coding RNAs and Inhibitors of Cancer-Related Carbonic Anhydrases.
Saghafi T; Taheri RA; Parkkila S; Emameh RZ
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208095
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.
Mishra S; Verma SS; Rai V; Awasthee N; Chava S; Hui KM; Kumar AP; Challagundla KB; Sethi G; Gupta SC
Cell Mol Life Sci; 2019 May; 76(10):1947-1966. PubMed ID: 30879091
[TBL] [Abstract][Full Text] [Related]
3. Role of lncRNAs in the cancer development and progression and their regulation by various phytochemicals.
Rathinasamy B; Velmurugan BK
Biomed Pharmacother; 2018 Jun; 102():242-248. PubMed ID: 29567536
[TBL] [Abstract][Full Text] [Related]
4. Targeting long non-coding RNAs in cancers: progress and prospects.
Li CH; Chen Y
Int J Biochem Cell Biol; 2013 Aug; 45(8):1895-910. PubMed ID: 23748105
[TBL] [Abstract][Full Text] [Related]
5. Modulation of long non-coding RNAs by resveratrol as a potential therapeutic approach in cancer: A comprehensive review.
Asemi R; Rajabpoor Nikoo N; Asemi Z; Shafabakhsh R; Hajijafari M; Sharifi M; Homayoonfal M; Davoodvandi A; Hakamifard A
Pathol Res Pract; 2023 Jun; 246():154507. PubMed ID: 37196467
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
Żołnowska B; Sławiński J; Pogorzelska A; Chojnacki J; Vullo D; Supuran CT
Eur J Med Chem; 2014 Jan; 71():135-47. PubMed ID: 24291567
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Supuran CT
Expert Opin Investig Drugs; 2018 Dec; 27(12):963-970. PubMed ID: 30426805
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Supuran CT; Winum JY
Future Med Chem; 2015; 7(11):1407-14. PubMed ID: 26230880
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).
Nocentini A; Supuran CT
Expert Opin Ther Pat; 2018 Oct; 28(10):729-740. PubMed ID: 30074415
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Winum JY; Scozzafava A; Montero JL; Supuran CT
Anticancer Agents Med Chem; 2009 Jul; 9(6):693-702. PubMed ID: 19601749
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Mboge MY; Chen Z; Wolff A; Mathias JV; Tu C; Brown KD; Bozdag M; Carta F; Supuran CT; McKenna R; Frost SC
PLoS One; 2018; 13(11):e0207417. PubMed ID: 30452451
[TBL] [Abstract][Full Text] [Related]
12. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
Puccetti L; Fasolis G; Vullo D; Chohan ZH; Scozzafava A; Supuran CT
Bioorg Med Chem Lett; 2005 Jun; 15(12):3096-101. PubMed ID: 15908204
[TBL] [Abstract][Full Text] [Related]
13. N-β-glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Rodríguez OM; Maresca A; Témpera CA; Bravo RD; Colinas PA; Supuran CT
Bioorg Med Chem Lett; 2011 Aug; 21(15):4447-50. PubMed ID: 21723123
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.
Sarikaya B; Ceruso M; Carta F; Supuran CT
Bioorg Med Chem; 2014 Nov; 22(21):5883-90. PubMed ID: 25267005
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNAs: a new frontier in the study of human diseases.
Shi X; Sun M; Liu H; Yao Y; Song Y
Cancer Lett; 2013 Oct; 339(2):159-66. PubMed ID: 23791884
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma.
He Y; Meng XM; Huang C; Wu BM; Zhang L; Lv XW; Li J
Cancer Lett; 2014 Mar; 344(1):20-27. PubMed ID: 24183851
[TBL] [Abstract][Full Text] [Related]
17. Epitranscriptomic Signatures in lncRNAs and Their Possible Roles in Cancer.
Dinescu S; Ignat S; Lazar AD; Constantin C; Neagu M; Costache M
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30654440
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated carbonic anhydrases and their inhibition.
Pastorekova S; Zatovicova M; Pastorek J
Curr Pharm Des; 2008; 14(7):685-98. PubMed ID: 18336315
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs: From disease code to drug role.
Chen Y; Li Z; Chen X; Zhang S
Acta Pharm Sin B; 2021 Feb; 11(2):340-354. PubMed ID: 33643816
[TBL] [Abstract][Full Text] [Related]
20. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII.
Ozensoy Guler O; Arslan O; Kockar F
Methods Find Exp Clin Pharmacol; 2008 Jun; 30(5):335-40. PubMed ID: 18806891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
